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A mouse model for HBV immunotolerance and
immunotherapy
Dan Yang1,2,#, Longchao Liu1,2,#, Danming Zhu1, Hua Peng1, Lishan Su3, Yang-Xin Fu1,4
and Liguo Zhang1
Lack of an appropriate small animal model remains a major hurdle for studying the immunotolerance and
immunopathogenesis induced by hepatitis B virus (HBV) infection. In this study, we report a mouse model with sustained
HBV viremia after infection with a recombinant adeno-associated virus (AAV) carrying a replicable HBV genome (AAV/
HBV). Similar to the clinical HBV carriers, the mice infected with AAV/HBV were sero-negative for antibodies against HBV
surface antigen (HBsAg). Immunization with the conventional HBV vaccine in the presence of aluminum adjuvant failed
to elicit an immune response against HBV in these mice. To identify a vaccine that can potentially circumvent this
tolerance, the TLR9 agonist CpG was added to HBsAg as an adjuvant. Vaccination of mice with HBsAg/CpG induced not
only clearance of viremia, but also strong antibody production and T-cell responses. Furthermore, both the DNA
replication and protein expression of HBV were significantly reduced in the livers of AAV/HBV-infected mice. Accordingly,
AAV/HBV-infected mice may be used as a robust model for investigating the underlying mechanism(s) of HBV
immunotolerance and for developing novel immunotherapies to eradicate HBV infections.
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INTRODUCTION
Over 350 million people worldwide are affected by chronic
hepatitis B (CHB), which remains the leading cause of liver
cancer in developing countries.1,2 Current hepatitis B virus
(HBV) treatments, including antiviral nucleos(t)ides and
alpha interferons, are administered to suppress viral replica-
tion but cannot induce a protective immune response or
viral clearance.2,3 Interruptions of these treatments would
result in unavoidable viral rebound. Moreover, long-term
treatment may be hampered by escape mutants, drug resis-
tance, side effects and heavy economic burdens. Novel treat-
ments, including therapeutic vaccines, are urgently needed
to effectively control the HBV epidemic and eventually eradi-
cate chronic HBV infection. However, the lack of a robust
animal model that closely mimics chronic HBV infection in
patients2,4 has hindered the development of novel treatments
for CHB.
Transgenic mice containing the HBV genome either persis-
tently express distinct HBV antigens or produce infectious
virions.5–7 Although such mouse models have been used to test
numerous drugs for HBV infection, the central tolerance
induced by the transgenic gene products, starting from as early
as the embryonic stage, makes the study of therapeutic HBV
vaccines in this model system difficult. Furthermore, these
mice are not suitable for monitoring viral clearance because
the integrated HBV genome persists in every mouse cell.5,7,8
Alternative models were developed by hydrodynamic injec-
tion (HDI) of the HBV genome into the tail vein.9 A later study
showed that HDI of the HBV genome, which was cloned into
an adeno-associated virus (AAV) vector, would lead to a stable
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HBV replication and long-lasting viremia due to AAV-
mediated immune suppression.10 Unfortunately, neonatal
and young mouse models of CHB could not be successfully
established using this procedure. In addition, high levels of
HBV, which are commonly detected in patients with CHB,
could not be produced in this model due to the induction of
immune clearance. This phenomenon has also been observed
in another mouse model infected by an adenovirus vector har-
boring the HBV genome.11
It has been reported that mice infected with a recombinant
AAV carrying the HBV genome (AAV/HBV) exhibited con-
tinuous viremia for more than 30 weeks.12–14 In the present
study, we further characterized the anti-HBV immune res-
ponse in AAV/HBV-infected mice and demonstrated that these
mice can be used as an appropriate model for examining the




C57BL/6 mice were purchased from Vital River Laboratories
(Beijing, China). Six- to eight-week-old male mice were used in
all experiments unless otherwise specified. All mice were
housed under controlled temperature and light conditions fol-
lowing the Institutional Animal Care guidelines. AAV/HBV
virus was provided by Beijing FivePlus Molecular Medicine
Institute (Beijing, China). This recombinant virus carries 1.3
copies of the HBV genome (genotype D, serotype ayw) and is
packaged in AAV serotype 8 (AAV8) capsids.
AAV/HBV infection
Adult C57BL/6 mice were injected with the indicated amounts
of recombinant virus (diluted to 200 ml with phosphate-buf-
fered saline) through tail vein injection. Neonatal mice (3 days
after birth) were infected with AAV/HBV through intraliver
injection. The mice were bled retro-orbitally at the indicated
time points to monitor HBV surface antigen (HBsAg), HBV e
antigen (HBeAg), HBs antibody (HBsAb) and HBV genomic
DNA in serum.
HBsAg vaccination
HBsAg with an aluminum-containing adjuvant (EngerixB;
GlaxoSmithKline Biological, Middlesex, UK) was used as a
control vaccine in some experiments. CpG (1826) was synthe-
sized by Life Technologies Corporation (Carlsbad, USA)
(TCCATGACGTTCCTGACGTT) and mixed with 2 mg of
HBsAg. All vaccines were injected subcutaneously.
HDI
HDI of the plasmid pBlue-HBV1.3 was performed according to
previous reports.9,10 In brief, various doses of endo-free plas-
mid DNA (extracted using a Qiagen kit) were diluted in a
volume of saline equivalent to 8% of the body weight of the
mouse. The total injection volume was administered within
5–8 s.
Serological and biochemical analysis
Serum was harvested by retro-orbital bleeding. Serum alanine
aminotransferase activity (ALT kit; BioSino Bio-technology
and Science Inc, Beijing, China) was determined using a
SpectraMax Plus spectrophotometer (Molecular Devices,
Sunnyvale, CA, USA) following the manufacturer’s instruc-
tions. HBV antigens and antibodies were monitored by
enzyme-linked immunosorbent assay (ELISA).
ELISA assay
Serum HBsAg was measured by ELISA (Shanghai Kehua Bio-
engineering Co., Ltd, Shanghai, China) according to the man-
ufacturer’s instructions. The lower limit of detection for
HBsAg was 0.5 ng/ml. Serum dilutions of 2.5- to 100-fold were
used to obtain values within the linear range of the standard
curve. HBsAb was analyzed on a precoated HBsAg plate and
developed by HRP-labeled anti-mouse IgG (Zhong Shan-
Golden Bridge Biological Technology Co., Ltd, Beijing,
China). Regarding the liver specimens, 50 mg of tissue was
homogenized in RIPA lysis buffer and centrifuged at 12
000 r.p.m. for 5 min. The supernatant was collected for
HBsAg ELISA according to the manufacturer’s instructions.
Real-time PCR
Serum HBV DNA was extracted from 100 ml of serum and
measured following the manufacturer’s instructions (Qiagen,
Hilden, Germany). Liver HBV DNA was extracted from
50 mg of liver tissues using a genomic DNA kit (TIANGEN
Biotech, Beijing, China). The DNA samples were analyzed by
real-time quantitative PCR (qPCR) using HBV-specific primers
(59-CACATCAGGATTCCTAGGACC-39; 59-GGTGAGTGAT-
TGGAGGTTG-39).
Mouse GAPDH was used as the control for quantification
(forward 59-GGTGAAGGTCGGTGTGAACG-39; reverse 59-
CTCGCTCCTGGAAGATGGTG-39).
Immunohistochemistry
Liver tissues were fixed with 10% neutral buffered formalin and
embedded in paraffin. After deparaffinization, the sections
were incubated with primary antibodies (polyclonal rabbit
anti-HBcAg; DAKO, Glostrup, Denmark) and the DAKO
Envision System. The sections were also counter stained with
hematoxylin.
Synthetic peptides and ELISPOT assay
ENV190 (VWLSVIWM) peptides and OVA257 (SIINFEKL)
peptides were synthesized by Invitrogen. All peptides were dis-
solved in dimethyl sulfoxide (DMSO) before use. The organs
were harvested at the indicated time points after immunization
with HBs plus CpG1826 vaccines. An enzymatic digestion
method was utilized for the isolation of intrahepatic lympho-
cytes. In brief, liver tissues were digested by collagenase IV
(Roche, Basel, Switzerland) at 37 uC for 15 min. The suspen-
sion was centrifuged at 30g for 1 min to remove hepatocytes.
Lymphocytes were then pelleted by centrifugation at 400g
for 10 min and further purified with 40% and 70% Percoll
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solutions by centrifuging at 800g for 20 min at room temper-
ature. Cells were collected from the interface, and red blood
cells were removed with ACK buffer to make a single-cell sus-
pension. For detecting an antigen-specific immune response,
liver lymphocytes (1.53105) were incubated for 48 h at 37 uC
in complete medium containing 10 mg/ml ENV190 peptide or
OVA257 peptide in an IFNc ELISPOT plate (Merck Millipore,
Billerica, Massachusetts, USA). After incubation, IFN-c secre-
tion was analyzed using a biotinylated anti-IFN-c antibody and
streptavidin-HRP (BD Biosciences, Franklin Lakes, New
Jersey, USA). Finally, spots were visualized with AEC substrate
and quantified with the auto-analyzing system.
Statistical analysis
Statistical analyses were performed using a two-tailed unpaired
t-test and Prism software (GraphPad Software, San Diego,
California, USA). P,0.05 was considered statistically significant.
RESULTS
AAV/HBV induces sustained viremia in neonatal and adult
mice
To determine whether injection of mice using the AAV/HBV
system could establish a persistent HBV infection with viremia
in immunocompetent mice, 531010 viral genome equivalents
(vg) of recombinant virus was intravenously injected into adult
C57BL/6 mice. All the mice (n512) became serum HBsAg-
positive by 14 days post-infection (Figure 1a). Importantly,
we observed that male hosts had higher HBsAg than female
hosts. This phenomenon is in accordance with clinical obser-
vations.15,16 We also found that neonatal mice became HBsAg-
positive after intrahepatic injection of 131010 or 231010 vg
AAV/HBV (n530, Figure 1b). This is the first mouse model
of persistent HBV viremia in an immunocompetent host after
neonatal infection.
To test the dose-dependent response of the AAV/HBV infec-
tion, we delivered three doses of AAV/HBV virus ranging from
231010 to 131011 vg per mouse and monitored HBV viremia
for an extended period of 3 months. We found that serum
HBsAg levels ranged from 319612 ng/ml to 24146171 ng/ml
(Figure 1c), correlating with the inoculation dosages. In addi-
tion, nearly 100% (263/265) of the injected mice became HBV-
positive during the 3-month time period (data not shown). The
viremia lasted for more than 1 year in high-dose AAV/HBV-
infected mice (Supplementary Figure 1a and b).
Additionally, HBeAg was also detected in the blood of
infected mice (Figure 1d), indicating active HBV replication
in this CHB model.17 HBV genomic DNA in the sera of infected
mice also exhibited a dose-dependent correlation. The HBV
DNA levels, ranging from 6.613106 to 7.203107 copies/ml
in the mice infected with 131011 vg AAV/HBV (Figure 1e),
are comparable to those of CHB patients in the immunotoler-
ant stage.18–20 Furthermore, the immunohistochemical stain-
ing for HBV core antigen (HBcAg) in liver cells from infected
mice revealed that the frequency of HBcAg-positive cells was
proportional to infection dose of AAV/HBV (Figure 1f). HBV
core proteins were not detected in any other organs (heart,
kidney or lung) by immunohistochemical staining (data not
shown). In addition, viral transcripts and replicative inter-
mediates were detected in the mouse liver, but not in the heart,
kidney or lung. This experimental evidence confirmed that
chronic HBV replication was restricted to the liver (data not
shown).
Immune response against HBV in AAV/HBV-infected mice
Given the lasting expression of HBV proteins, we then exa-
mined whether this chronicity could provoke host immune
responses against viral antigens. We used an HBV plasmid
hydrodynamic injection model as the positive control for an
anti-HBV response.9 The pBlue-HBV1.3 plasmid contains an
HBV sequence identical to that in AAV/HBV. These control
mice developed high-titer anti-HBs antibody (HBsAb)
(Figure 2a). However, HBsAb could not be detected in the mice
receiving AAV/HBV. This suggests that AAV/HBV infection is
more physiologically accurate than plasmid hydrodynamic
injection for modeling persistent HBV infection and immuno-
tolerance with a wider range of viremia.
To address whether AAV/HBV chronic infection causes
liver damage, serum samples were collected from mice
infected with different doses of AAV/HBV and measured
for alanine aminotransferase (ALT) activity, a key indicator
of hepatic injury. No significant increase in ALT was
observed in infected adult mice over a 6-month period
(Figure 2b and Figure 1c). No obvious infiltrating lympho-
cytes or other abnormalities were observed in the infected
liver tissue by hematoxylin and eosin (H&E) staining
(Figure 2c). These results indicate that AAV/HBV infection
did not induce detectable liver injury.
Induction of HBV immune tolerance in AAV/HBV-infected
mice
In CHB patients, seroconversion to HBsAb is considered to
be a marker of disease resolution. However, the induction of
HBsAb is a challenging clinical goal to achieve due to HBV-
induced tolerance. We tested whether mice infected with
AAV/HBV virus could resist the challenge of a conventional
HBsAg vaccine, as observed in HBV infections. We used a
clinical HBV vaccine with aluminum adjuvant (Engerix-B).
Whereas naive mice developed considerable antibodies
against HBsAg at day 28 post-vaccination, AAV/HBV-
infected mice failed to develop anti-HBsAg antibody res-
ponses, which indicated immune tolerance toward HBsAg
(Figure 3a). By 42 days post-vaccination, none of the
AAV/HBV-infected mice that received Engerix-B treatment
showed significant reduction of serum HBsAg or HBeAg
when compared with the unimmunized mice (Figure 3b
and c). To detect the HBsAg-specific T-cell toler-
ance in this model, we challenged the AAV/HBV (131011
vg)-infected mice with HBsAg plus CpG and analyzed HBsAg-
specific CD8 T cells in the liver using IFN-c ELISPOT. AAV/
HBV-infected mice generated very low levels of IFN-c-producing
T cells compared with naive mice after vaccination (Figure 3d).
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Therapeutic vaccination with CpG adjuvant in AAV/HBV-
infected mice
To explore an effective vaccine that is capable of breaking
immune tolerance, we reconstituted the conventional HBsAg
vaccine with a strong TLR9 agonist, CpG, as an adjuvant.
HBV carrier mice that received 231010 vg AAV/HBV were
vaccinated with an equal amount of HBsAg in the presence
of either 1 or 50 mg of CpG1826 and subsequently boosted with
Engerix-B. HBsAg levels rapidly declined after vaccination and
remained undetectable without rebound (Figure 4a). HBsAb
induction is a clinical indication of immune protection. More












































































































Figure 1 AAV/HBV inoculation resulted in persistent HBV viremia in immunocompetent mice. (a) Female or male C57BL/6 mice (n56, 6–8 weeks
old) were infected with AAV/HBV at 531010 viral genome equivalents (vg) through tail vein injection. At 14 days post-infection, blood samples were
collected and serum HBsAg was measured by ELISA. (b) Intraliver injection of 3-day-old neonatal C57BL/6 mice (n56–7) was performed with
131010 or 231010 vg AAV/HBV, and serum HBsAg titers were examined at 48 days post-infection. (c) C57BL/6 mice (n56, 6–8 weeks old) were
infected with AAV/HBV at 231010, 531010 or 131011 vg. The mice were bled biweekly after infection. Serum HBsAg was measured by ELISA. The
lower limit of detection was 0.5 ng/ml. (d) Adult C57BL/6 mice were intravenously injected with 231010, 531010 or 131011 vg virus and were bled
biweekly to monitor serum HBeAg titers. (e) On day 40 post-AAV/HBV infection, HBV genomic DNA in the serum was determined by real-time PCR.
(f) Immunohistochemical staining of HBcAg in the liver of AAV/HBV infected mice (12 weeks post-infection). AAV, adeno-associated virus; HBcAg,
HBV core antigen; HBsAg, HBV surface antigen; HBV, hepatitis B virus.
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Figure 3 AAV/HBV infection induces immune tolerance. (a) Adult mice were infected with 131011 vg AAV/HBV followed by Engerix-B immu-
nization at 3 weeks post-infection. Serum HBsAb levels were monitored by ELISA at 4 weeks post-vaccination. Uninfected mice immunized with
Engerix-B and non-immunized AAV/HBV-infected mice were chosen as controls (n55). (b) The serum HBsAg titer was monitored by ELISA at
different time points pre- and post-Engerix-B immunization (n53). The arrow indicates vaccine immunization. (c) Following the same immu-
nization protocol, the HBeAg titer was measured by ELISA (n53). The arrow indicates vaccine immunization. (d) Adult mice infected with AAV/HBV
(131011 vg) were treated with HBsAg (2 mg/mouse) plus CpG (50 mg per mouse) at 3 weeks post-infection and euthanized on day 10 post-
vaccination. ENV190-specific CD8 T cells of liver leukocytes were detected by IFN-c ELISPOT (n53). AAV, adeno-associated virus; HBeAg, HBV e
antigen; HBsAg, HBV surface antigen; HBV, hepatitis B virus.


































Figure 2 The immune response was undetectable in AAV/HBV-infected mice. (a) Serum HBsAb levels in C57BL/6 mice receiving 15 mg of pBlue-
HBV1.3 DNA via hydrodynamic injection or infected with 131011 vg of AAV/HBV (n53). (b) ALT levels of HBV carrier mice were measured over
time (n53). (c) H&E staining of liver sections from mice infected with different doses of AAV/HBV. One of two independent experiments is
presented. AAV, adeno-associated virus; ALT, alanine aminotransferase; HBsAg, HBV surface antigen; HBV, hepatitis B virus; H&E, hematoxylin
and eosin.
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developed protective anti-HBsAbs in a dose-dependent man-
ner, as vaccination with a low dose of CpG as an adjuvant failed
to induce protective anti-HBsAbs (Figure 4b). There was no
significant upregulation of ALT in either of the vaccinated
groups (Figure 4c). Because CD81 T-cell responses are an
important indicator of anti-viral immune responses and
immune clearance, we examined whether this CpG-adjuvant
vaccine could induce an HBsAg-specific CD81 T-cell response.
Indeed, vaccination with HBsAg plus a high dose of CpG
(50 mg) provoked a stronger ENV190-specific CD81 T-cell
response in the liver (Figure 4d). These data indicate that an
HBsAg vaccine containing a proper dose of the CpG adjuvant
may have a potent therapeutic effect in carriers with low-level
viremia and could restore the host immune response to HBV.
However, carriers with high-level viremia (mice infected
with 131011 vg) failed to respond to HBsAg plus CpG vaccina-
tion, as the level of HBsAg in the blood and liver tissue was not
reduced (Supplementary Figure 2). The means by which a
proper antibody response can be induced in mice with such
severe viremia remains to be determined.
Vaccination with a CpG adjuvant leads to a reduction of
HBV in the liver
Although HBsAg serological conversion is the currently accepted
marker for a cured HBV infection, viral DNA may still be present
in the liver, which could result in viral rebound when the immune
system is suppressed.21–23 Thus, clearance of HBV DNA in the
liver is considered as the ultimate goal of anti-HBV therapy. To
evaluate the therapeutic effect of vaccination with CpG adjuvant,
we tested the HBV DNA level from liver extracts by real-time PCR
at 11 weeks post-vaccination. Interestingly, we found that HBV
DNA replication in the liver decreased after vaccination with high-
dose CpG (50 mg) but not low-dose CpG (1 mg) (Figure 5a).
Meanwhile, HBsAg in the liver was significantly reduced in mice
that received high-dose CpG compared with those that received
low-dose CpG vaccination (Figure 5b). Furthermore, HBcAg, an
important marker for HBV replication, was also remarkably
decreased in the high-dose CpG vaccination group (Figure 5c).
DISCUSSION
It was recently reported that AAV/HBV infection in mice estab-
lished persistent viremia for more than 30 weeks.12,13 Here, we
further reveal that male mice exhibit a higher plasma viral load
than females. The AAV/HBV-infected mice lacked an anti-
HBV immune response regardless of the levels of HBV viremia
present. Furthermore, these mice were resistant to immuniza-
tion with the conventional vaccine with aluminum adjuvant,
which is an indication of immune tolerance. These findings are
similar to clinical observations in HBV-infected patients and
demonstrate that these AAV/HBV-infected mice can be
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Figure 4 AAV/HBV-infected mice respond to HBsAg vaccination with CpG. (a) C57BL/6 mice were infected with AAV/HBV (231010 vg) and were
subsequently immunized with HBsAg plus CpG (50 or 1 mg per mouse) at 3 weeks post-infection (wpi) followed by a boost with Engerix-B (2 mg/mouse) at
7 wpi. Serum HBsAg levels in the different groups were monitored by ELISA (n53). (b) HBsAb titers were measured by ELISA. (c) The ALT in immunized
mice was monitored at different time points post-vaccination. (d) AAV/HBV (231010 vg)-infected mice were treated with HBsAg plus two respective
doses of CpG (50 or 1 mg per mouse) or high-dose CpG alone at 3 wpi. ENV190-specific CD81 T cells in the liver were detected by IFN-c ELISPOT at 10
days post-vaccination (n55). AAV, adeno-associated virus; ALT, alanine aminotransferase; HBsAg, HBV surface antigen; HBV, hepatitis B virus.
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utilized as a robust model to study immunotolerance induced
by HBV infection.
With the same AAV/HBV infection model, Dion et al.24
reported that HBV-specific CD81 T cells could be detected
in both peripheral lymphoid and liver tissues upon immuniza-
tion with a DNA vaccine expressing HBsAg. However, despite
the presence of HBV-specific T-cell responses, all infection
markers remained unchanged at 2 weeks post-immunization,24
including the levels of plasma HBeAg and HBsAg, intrahepatic
expression of HBcAg and HBV DNA replication intermediates.
This piece of experimental data is similar to that obtained from
the clinical trial of a DNA vaccine,25 which highlights the com-
plexity of HBV-induced dysfunction of the immune system.
Moreover, significant liver inflammation and liver damage
in AAV/HBV-infected mice, manifested by increased ALT
levels, fibrosis and steatosis, were reported by another group.
In addition, 100% of these mice (12 out of 12) developed visible
tumor nodules in the liver within 16 weeks.26 We did not
observe any tumor formation in 33 HBV-infected mice that
had been monitored for more than 1 year, although we used the
same HBV strain (a genotype D virus). In our study, one AAV
construct containing the entire HBV genome was used,
whereas Tao et al.27 used two AAVs each containing one half
of the HBV genome. However, whether this difference in AAV
constructs contributes to liver cancer formation remains to be
determined in the future.
Using our new HBV infection model, we demonstrated the
therapeutic potential of vaccines containing CpG as an adju-
vant. CpG is an oligodeoxynucleotide containing unmethylated
CpG motifs. It serves as a ‘danger signal’ to improve dendritic
and B cell functions through Toll-like receptor 9 signaling.28–30
A clinical trial of an HBV vaccine with CpG adjuvant showed
significant improvement over a conventional vaccine with alu-
minum adjuvant.31–34 Immunization with CpG adjuvant pro-
motes Th1 immune cell differentiation, which inhibits the
replication of intracellular pathogens.35 The data presented here
provide further support that CpG may serve as a potential
adjuvant for an HBV therapeutic vaccine.
In summary, we have demonstrated that AAV/HBV-infected
mice are a new and clinically relevant model that may be used
for delineating the mechanism of HBV-induced immunotoler-
ance and for developing therapeutic vaccines or other novel
immunotherapies to eradicate HBV infections.
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Figure 5 Vaccination with CpG adjuvant reduces HBV DNA in the liver. (a) AAV/HBV (231010 vg)-infected mice were treated with the indicated
vaccine combinations. HBV DNA levels in the liver were determined by real-time PCR at 11 weeks post-vaccination. (b) HBsAg levels in the liver
were measured by ELISA at 11 weeks post-vaccination with homogenized liver tissues. (c) Immunohistochemical staining of HBcAg in the liver
sections of different groups (n53). AAV, adeno-associated virus; HBcAg, HBV core antigen; HBsAg, HBV surface antigen; HBV, hepatitis B virus.
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